Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET | Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
sphericalinsightsoptionblue.png
Global Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61%
March 13, 2024 05:00 ET | SPHERICAL INSIGHTS LLP
New York, United States, March 13, 2024 (GLOBE NEWSWIRE) -- The Global Psychedelic Drugs Market Size is to Grow from USD 2.9 Billion in 2023 to USD 8.7 Billion by 2033, at a Compound Annual Growth...
Apellis logo.jpg
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024 07:00 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief...
SKYE Logo.png
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
March 04, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
Compass-Logo-Black++(1).png
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 
February 29, 2024 07:00 ET | Compass Pathways
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET | Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Apellis logo.jpg
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 07:05 ET | Apellis Pharmaceuticals, Inc.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than...
22157.jpg
Molecular Diagnostics at Point of Care: Comprehensive Insights into the Rapid Market Growth and Advances from 2023-2027
February 22, 2024 11:58 ET | Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 -...
logo.png
Healthcare Automation Market Size Projected to Reach USD 80.28 Bn by 2032
February 22, 2024 10:20 ET | Precedence Research
Ottawa, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The healthcare automation market size stood at USD 37.71 billion in 2024 and is expected to surpass around USD 56.39 billion by 2029, according to a study...
Dr Bob logo.jpg
Spinal Rehab & Sports Medicine Announces Dr. Bob Meyer's 25-Year Anniversary in Sports Medicine
February 21, 2024 10:30 ET | Spinal Rehab Sports Medicine
AUSTIN, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spinal Rehab & Sports Medicine proudly announces Dr. Bob Meyer, D.C. unparalleled expertise in sports medicine, serving the vibrant community of...